EquityNet Research Initiates Independent Analyst Coverage of Huifeng Bio-Pharmaceutical Technology

XI'AN, China, Dec. 21 /PRNewswire-Asia/ -- Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, today reported that after preliminary due diligence, including review of the company's market potential and development opportunities, EquityNet Research is initiating coverage of the company as an independent analyst.

Founded 10 years ago, the Los Angeles, Calif.-based research firm provides the investing public with professional, independent, objective research on under-followed public companies. It does this by preparing detailed research that highlights the key aspects of the company and its industry. Two of the firm's three principals are holders of the Chartered Financial Analyst (CFA) designation.

"Independent research provides a benchmark by which potential investors can gauge a company's fair value, eliminating such extraneous factors as supply and demand issues," said EquityNet Founder and Senior Equity Analyst Randall Lewis. "And perhaps most importantly, it is a statement by management to current shareholders and investors that, 'We have enough confidence in our company and future to compensate an independent analyst to perform a fair, accurate valuation of our stock, just like private companies do all the time.' This shows at least that the company feels it has nothing to hide, and has self-assurance in its business model."

Lewis pointed out that according to a survey by Charles Schwab & Co., reported in The New York Times, an astonishing 78% of active stockholders now "value research from independent firms over analysis by Wall Street firms with financial ties to the companies they are rating..."

EquityNet Research expects to publish its initial coverage of Huifeng Bio-Pharmaceutical in January 2010.

About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB)

Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties in Xi'an China. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. Additional information is available at the Company's website: http://www.hfgb.cn/

Safe Harbor Statement

This press release may contain forward-looking statements. These statements are based on the current expectations or beliefs of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements, including but not limited to the fluctuation of prices of raw materials, the market demand for our products, changes in governmental regulations and/or economic policies and our ability to penetrate new markets.

For more information, please contact:

Tom Gavin

Investor Relations Network

Phone: +1-951-845-1112

Email: irnetwork@earthlink.net

Related stocks: OTC:HFGB